155 related articles for article (PubMed ID: 37096814)
1. TRPS1 outperforms GATA3 in pleural effusions with metastatic breast carcinoma versus mesothelioma.
Baban F; Koepplin JW; Ahmad M; Clarke-Brodber AL; Bois MC; Hartley CP; Sturgis CD
Diagn Cytopathol; 2023 Aug; 51(8):488-492. PubMed ID: 37096814
[TBL] [Abstract][Full Text] [Related]
2. Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma.
Bradt A; Jing X; Smola BS; Lew M
Diagn Cytopathol; 2023 Nov; 51(11):665-673. PubMed ID: 37461248
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens.
Chen CJ; Hang JF; Chen YA; Lin SJ; Chiu HM; Hsu CY; Lai CR; Yang CS
Cancer Cytopathol; 2023 Apr; 131(4):226-233. PubMed ID: 36399408
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility and sensitivities of matrix Gla protein (MGP), TRPS1 and GATA3 in breast cancer: focusing on metastatic breast cancer, invasive breast carcinoma with special features, and salivary gland-type tumours.
Wu Y; Chen F; Pan L; Chao X; Li M; Luo R; Chen K; Zheng C; Du T; He J; Sun P
Pathology; 2024 Jun; 56(4):516-527. PubMed ID: 38570266
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of TRPS1 Expression in Pleural Effusion Cytology Specimens With Metastatic Breast Carcinoma.
Wang M; Stendahl K; Cai G; Adeniran A; Harigopal M; Gilani SM
Am J Clin Pathol; 2022 Sep; 158(3):416-425. PubMed ID: 35760555
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
[TBL] [Abstract][Full Text] [Related]
7. Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.
Du T; Pan L; Zheng C; Chen K; Yang Y; Chen J; Chao X; Li M; Lu J; Luo R; Zhang J; Wu Y; He J; Jiang D; Sun P
Breast Cancer Res; 2022 Oct; 24(1):70. PubMed ID: 36284362
[TBL] [Abstract][Full Text] [Related]
8. Trichorhinophalangeal Syndrome Type 1 Is a Highly Sensitive and Specific Marker for Diagnosing Triple-Negative Breast Carcinomas on Cytologic Samples.
Lynn TJ; Shi J; Liu H; Monaco SE; Prichard JW; Lin F
Arch Pathol Lab Med; 2024 Jan; 148(1):e1-e8. PubMed ID: 37406296
[TBL] [Abstract][Full Text] [Related]
9. TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?
Bachert SE; Di J; Zhang S; Short HE; Piecoro DW; McDonald RJ; Myint ZW; Hensley PJ; Allison DB
Hum Pathol; 2024 Jan; 143():42-49. PubMed ID: 38052269
[TBL] [Abstract][Full Text] [Related]
10. Trichorhinophalangeal syndrome type 1 (TRPS1) expression in male breast carcinoma.
Law T; Piotrowski MJ; Ning J; Jiang X; Ding Q; Sahin AA
Hum Pathol; 2023 Aug; 138():62-67. PubMed ID: 37331526
[TBL] [Abstract][Full Text] [Related]
11. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.
Yoon EC; Wang G; Parkinson B; Huo L; Peng Y; Wang J; Salisbury T; Wu Y; Chen H; Albarracin CT; Resetkova E; Middleton LP; Krishnamurthy S; Gan Q; Sun H; Huang X; Shen T; Chen W; Parwani AV; Sahin AA; Li Z; Ding Q
Hum Pathol; 2022 Jul; 125():97-107. PubMed ID: 35413381
[TBL] [Abstract][Full Text] [Related]
12. A pilot study: Comparison of TRPS1 and GATA3 immunoperoxidase staining using cytologic smears in entities reportedly positive for GATA3.
Rohra P; Ding C; Yoon EC; Gan Q
Cancer Cytopathol; 2022 Dec; 130(12):930-938. PubMed ID: 35790088
[TBL] [Abstract][Full Text] [Related]
13. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
14. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
15. TRPS1 is a Highly Sensitive Marker for Breast Cancer: A Tissue Microarray Study Evaluating More Than 19,000 Tumors From 152 Different Tumor Entities.
Lennartz M; Löhr N; Höflmayer D; Dwertmann Rico S; von Bargen C; Kind S; Reiswich V; Viehweger F; Lutz F; Bertram V; Fraune C; Gorbokon N; Weidemann S; Blessin NC; Hube-Magg C; Menz A; Schlichter R; Krech T; Hinsch A; Burandt E; Sauter G; Simon R; Kluth M; Marx AH; Lebok P; Dum D; Minner S; Jacobsen F; Clauditz TS; Bernreuther C; Steurer S
Am J Surg Pathol; 2024 Jun; 48(6):637-651. PubMed ID: 38647255
[TBL] [Abstract][Full Text] [Related]
16. Utility of Immunohistochemistry for MUC4 and GATA3 to Aid in the Distinction of Pleural Sarcomatoid Mesothelioma From Pulmonary Sarcomatoid Carcinoma.
Terra SBSP; Roden AC; Aubry MC; Yi ESJ; Boland JM
Arch Pathol Lab Med; 2021 Feb; 145(2):208-213. PubMed ID: 33501493
[TBL] [Abstract][Full Text] [Related]
17. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study.
El Hag MI; Ha J; Farag R; El Hag AM; Michael CW
Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760
[TBL] [Abstract][Full Text] [Related]
18. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation.
Wang J; Peng Y; Sun H; Aung PP; Resetkova E; Yam C; Sahin AA; Huo L; Ding Q
Arch Pathol Lab Med; 2024 Feb; 148(2):200-205. PubMed ID: 37074839
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
Ordóñez NG; Sahin AA
Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068
[TBL] [Abstract][Full Text] [Related]
20. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
Ai D; Yao J; Yang F; Huo L; Chen H; Lu W; Soto LMS; Jiang M; Raso MG; Wang S; Bell D; Liu J; Wang H; Tan D; Torres-Cabala C; Gan Q; Wu Y; Albarracin C; Hung MC; Meric-Bernstam F; Wistuba II; Prieto VG; Sahin AA; Ding Q
Mod Pathol; 2021 Apr; 34(4):710-719. PubMed ID: 33011748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
